Latest News From "The Pink Sheet" DAILY - Qnexa May Launch Despite Panel's No Vote

Bioniche Purchase Will Move Mylan Into Generic Injectables Market

Bioniche Pharma will be combined with UDL Laboratories to create new Mylan Institutional unit.   read more

 

Qnexa May Get Staged Launch After No Vote From Advisory Committee

Safety concerns and a large market potential for Vivus's obesity drug combine to produce an advisory panel recommendation that leaves FDA "a little surprised."   read more

 

Novartis Reports Strong Growth From New Products

Diversification, new products, and new indications for existing products helped Novartis weather downward pressure from global currency and pricing cuts in the first half of 2010.   read more

 

Regeneron Lays Out Commercial Case For Arcalyst In Gout Flares To Investors; Convincing Payers May Be Challenge

During the biopharma's first ever investor day, management outlines early plans for the launch of Arcalyst for the prevention of gout flares.   read more

 

CMS Chief Berwick's Appointment May Not Close Door To Near-Term Senate Hearings

Republicans on the Senate Finance Committee formally request that the committee hold a hearing with Don Berwick following his recess appointment; Chairman Baucus is receptive to a hearing soon to discuss health reform.   read more

 

UK's Coalition Government To Look For More Value In Prescription Medicines

Change is afoot in the UK's National Health Service, where the new government hopes to get more "value" for its pharmaceutical bill while at the same time expanding access to cancer drugs.   read more

 

Novartis Will Track Gender Disparities In Performance Evaluations Under Settlement

Gender discrimination suit is resolved with Novartis paying $175 million, 45 percent less than a jury awarded plaintiffs.   read more

 

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here